Appendix 1: Supplementary tables [posted as supplied by author] Table A. Details of MeSH Search Terms
|
|
|
- Nickolas Morton
- 5 years ago
- Views:
Transcription
1 Appendix 1: Supplementary tables [posted as supplied by author] Table A. Details of MeSH Search Terms Stent Bare Metal Stent Drug Eluting Stent MeSH terms Randomized controlled trial, clinical trial, Human, Diabetes, Bare metal stent, Vision, Bx velocity, Millenium, Multilink vision Randomized controlled trial, clinical trial, Human, Diabetes, Drug eluting stent, Eluting stent, Paclitaxel, Sirolimus, Everolimus, 1
2 Appendix Table B. Sensitivity Analysis: Select Outcomes in Trials with Low-bias Risk Reference Comparator TVR Death RR (95% Cr I) RR (95% Cr I) Bare Metal Sirolimus MI RR (95% Cr I) Any ST RR (95% Cr I) 0.37 (0.28, 0.46) 0.99 (0.72, 1.36) 0.75 (0.51, 1.03) 0.67 (0.34, 1.35) Paclitaxel 0.47 (0.35, 0.62) 1.01 (0.67, 1.44) 0.80 (0.52, 1.14) 0.83 (0.37, 1.69) Everolimus 0.30 (0.18, 0.45) 0.88 (0.42, 1.56) 0.49 (0.20, 0.94) 0.58 (0.18, 1.62) 0.60 (0.40, 0.93) 1.20 (0.62, 2.26) 2.52 (0.92, 7.01) 3.61 (0.81, 19.51) Sirolimus Paclitaxel 1.26 (1.00, 1.68) 1.01 (0.70, 1.39) 1.08 (0.72, 1.53) 1.19 (0.63, 2.43) Everolimus 0.81 (0.54, 1.17) 0.88 (0.45, 1.56) 0.64 (0.28, 1.24) 0.85 (0.32, 2.21) 1.61 (1.12, 2.47) 1.22 (0.65, 2.16) 3.33 (1.30, 8.41) 5.35 (1.40, 31.05) Paclitaxel Everolimus 0.63 (0.41, 0.91) 0.87 (0.44, 1.44) 0.61 (0.28, 1.12) 0.71 (0.26, 1.70) 1.28 (0.85, 1.94) 1.18 (0.62, 2.34) 3.12 (1.19, 8.01) 4.32 (1.18, 23.58) Everolimus 2.00 (1.24, 3.61) 1.37 (0.64, 3.34) 5.28 (1.68, 15.84) 6.16 (1.29, 40.22) Cr I = credibility interval; MI = myocardial infarction; ST = stent thrombosis; TVR= target vessel revascularization 2
3 Appendix Table C. Sensitivity Analysis: Select Outcomes in Non-ACS Trials Reference Comparator TVR Death RR (95% Cr I) RR (95% Cr I) Bare Metal Sirolimus MI RR (95% Cr I) Any ST RR (95% Cr I) 0.33 (0.22, 0.46) 0.94 (0.60, 1.45) 0.64 (0.38, 1.02) 0.61 (0.16, 1.84) Paclitaxel 0.41 (0.27, 0.57) 0.92 (0.57, 1.43) 0.69 (0.40, 1.13) 0.87 (0.25, 3.01) Everolimus 0.26 (0.14, 0.43) 0.79 (0.35, 1.66) 0.42 (0.13, 0.90) 0.54 (0.10, 2.59) 0.71 (0.38, 1.28) 1.27 (0.53, 2.97) 5.52 (1.08, 74.24) 7.41 (0.53, ) Sirolimus Paclitaxel 1.21 (0.91, 1.63) 0.98 (0.66, 1.40) 1.07 (0.69, 1.65) 1.41 (0.69, 3.81) Everolimus 0.79 (0.48, 1.19) 0.84 (0.42, 1.55) 0.65 (0.23, 1.29) 0.86 (0.27, 3.18) 2.12 (1.20, 3.85) 1.35 (0.61, 2.93) 8.44 (1.93, 126.7) (1.53, ) Paclitaxel Everolimus 0.65 (0.38, 0.98) 0.86 (0.44, 1.56) 0.61 (0.22, 1.14) 0.62 (0.16, 2.02) 1.74 (0.95, 3.16) 1.39 (0.57, 3.04) 8.04 (1.71, 106.3) 7.99 (0.91, 120.1) Everolimus 2.67 (1.37, 5.76) 1.60 (0.58, 4.33) (2.58, 240.5) (1.29, ) ACS = acute coronary syndromes; Cr I = credibility interval; MI = myocardial infarction; ST = stent thrombosis; TVR= target vessel revascularization 3
4 Appendix Table D. Direct comparison analysis for select outcomes (Random effects model) Treatment Control TVR Death MI Any ST RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) Sirolimus Bare Metal Def/Prob ST RR (95% CI) 0.41 (0.31, 0.54) 1.09 (0.78, 1.51) 0.79 (0.54, 1.15) 0.79 (0.41, 1.53) 0.80 (0.32, 2.02) Paclitaxel Bare Metal 0.55 (0.41, 0.73) 0.91 (0.60, 1.37) 0.78 (0.51, 1.20) 0.75 (0.33, 1.69) 0.69 (0.24, 1.94) Everolimus Bare Metal Bare Metal 0.50 (0.23, 1.06) Paclitaxel Sirolimus 1.15 (0.87, 1.52) 1.05 (0.78, 1.42) 1.28 (0.85, 1.93) 1.22 (0.64, 2.30) 1.08 (0.24, 4.90) Everolimus Sirolimus 0.70 (0.47, 1.04) 0.43 (0.20, 0.94) 0.16 (0.03, 0.90) 0.67 (0.24, 1.88) 0.51 (0.13, 2.09) Sirolimus 2.01 (0.97, 4.14) 1.28 (0.74, 2.22) 3.35 (0.88, 12.67) 2.71 (0.60, 12.21) 1.02 (0.06, 16.26) Everolimus Paclitaxel 0.86 (0.63, 1.17) 1.36 (0.80, 2.31) 0.86 (0.55, 1.34) 0.79 (0.39, 1.61) 0.79 (0.39, 1.61) Paclitaxel 1.08 (0.67, 1.75) 0.81 (0.15, 4.40) 1.84 (0.43, 7.89) 4.06 (0.68, 24.43) 2.94 (0.31, 28.04) Everolimus CI = confidence interval; MI = myocardial infarction; ST = stent thrombosis; TVR= target vessel revascularization 4
5 Appendix Table E. Between trial heterogeneity: Estimates of the between-trial variance τ 2 Outcome τ 2 τ 2 (Model Restricted to Low- τ 2 (Model Restricted to Trials (Overall Model) Bias Risk Trials) with Clopidogrel >6 m) Target Vessel Revascularization Target Lesion Revascularization Death Myocardial Infarction Any Stent Thrombosis Definite Stent Thrombosis Definite or Probable Stent Thrombosis A τ 2 estimate of 0.04 is interpreted as a low, 0.14 as a moderate and 0.40 as a high degree of heterogeneity between trials. 5
6 Appendix Table F. Evaluation of model fit: Network of all trials Mean of residual N (%) of residuals Satisfactory Outcome N of Data Points deviance within ± 1.96 of SND Q-Q plot Target Vessel Revascularization (100%) Yes Target Lesion Revascularization (100%) Yes Death (98.6%) Yes Myocardial Infarction (100%) Yes Any Stent Thrombosis (98.6%) Yes Definite Stent Thrombosis (98.5%) Yes Definite or Probable Stent Thrombosis (100%) Yes The model was considered to provide an adequate fit to the data if (i) the mean of the residual deviance was similar to the number of data points used in the model, (ii) at least 95% of means of standardized nodebased residuals were within ± 1.96 of the standard normal distribution, and (iii) Q Q plots of residuals lied closely around a line on visual inspection. SND, Standard Normal Distribution 6
7 Appendix Table G. Evaluation of model fit: Model restricted to trials with low bias risk Mean of residual N (%) of residuals Satisfactory Outcome N of Data Points deviance within ± 1.96 of SND Q-Q plot Target Vessel Revascularization (100%) Yes Target Lesion Revascularization (100%) Yes Death (98.5%) Yes Myocardial Infarction (100%) Yes Any Stent Thrombosis (98.4%) Yes Definite Stent Thrombosis (98.3%) Yes Definite or Probable Stent Thrombosis (100%) Yes The model was considered to provide an adequate fit to the data if (i) the mean of the residual deviance was similar to the number of data points used in the model, (ii) at least 95% of means of standardized nodebased residuals were within ± 1.96 of the standard normal distribution, and (iii) Q Q plots of residuals lied closely around a line on visual inspection. SND, Standard Normal Distribution 7
8 Appendix Table H. Evaluation of model fit: Model restricted to trials with clopidogrel duration >6 months Mean of residual N (%) of residuals Satisfactory Outcome N of Data Points deviance within ± 1.96 of SND Q-Q plot Target Vessel Revascularization (100%) Yes Target Lesion Revascularization (100%) Yes Death (98.4%) Yes Myocardial Infarction (100%) Yes Any Stent Thrombosis (98.2%) Yes Definite Stent Thrombosis (98.2%) Yes Definite or Probable Stent Thrombosis (100%) Yes The model was considered to provide an adequate fit to the data if (i) the mean of the residual deviance was similar to the number of data points used in the model, (ii) at least 95% of means of standardized nodebased residuals were within ± 1.96 of the standard normal distribution, and (iii) Q Q plots of residuals lied closely around a line on visual inspection. SND, Standard Normal Distribution 8
Coronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
DES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
Smooth muscle pharmacology & interventional cardiology
LAST LECTURE Smooth muscle & interventional cardiology By: Pascal Bernatchez Classic Vascular -chronic -systemic Local Vascular -acute -targeted High blood pressure Blood pressure control Atherosclerosis
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Bagust A, Grayson A D, Palmer N D, Perry R A, Walley T
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Bagust A, Grayson A D, Palmer N D, Perry R A, Walley T Record Status This is a critical abstract of an economic
Bern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
Supplementary Online Content
Supplementary Online Content Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand S-LT, Rumsfeld JS, Messenger JC, Yeh RW. Use of
Supplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
Long-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
www.nature.com/scientificreports Received: 11 October 2016 Accepted: 16 June 2017 Published online: 25 July 2017 OPEN Long-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES
BMS vs. DES vs. CABG
A Collaborative Systemic Review and Meta-Analysis of A Results from 3976 Patients: BMS vs. DES vs. CABG Overall Safety and Efficacy Issues of Left Main Intervention Duk-Woo Park, MD, PhD University of
Supplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Byrne RA, Stone GW, Ormiston J, Kastrati A.
Xinlin Zhang, Jun Xie, Guannan Li, Qinhua Chen, Biao Xu* Abstract. Introduction
Head-to-Head Comparison of Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of 76 Studies Xinlin Zhang, Jun Xie, Guannan
Biosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
ST-Elevation MI: Update on Bivalirudin and DES
ST-Elevation MI: Update on Bivalirudin and DES George D. Dangas, MD, FACC, FSCAI, FAHA Professor of Medicine Director, Cardiovascular Innovation Mount Sinai Medical Center, New York, NY Disclosure Research
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst, Giovanna Sarno, Göran Olivecrona, Per Tornvall, Johan
The MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET)
7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET) Hiroki Shiomi, MD Kyoto University Graduate School of Medicine
Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
Clinical Study Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
Thrombosis Volume 2012, Article ID 126369, 8 pages doi:10.1155/2012/126369 Clinical Study Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized
Abstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
Osler Journal Club Outcomes Research
Osler Journal Club Outcomes Research Malenka DJ, et al. Outcomes Following Coronary Stenting in the Era of Bare-Metal vs. the Era of Drug- Eluting Stents. JAMA 2008; 299(24):2868-2876 Mentor: Dr. Boulware
1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
Netzwerk-Meta-Analysen und indirekte Vergleiche: Erhoḧte (Un)Sicherheit?
Netzwerk-Meta-Analysen und indirekte Vergleiche: Erhoḧte (Un)Sicherheit? Prof. Peter Jüni MD FESC Institute of Social and Preventive Medicine and CTU Bern, University of Bern Is there increased certainty?
Coronary Stents: Past, Present and Future
Kardiologie Kardio Lunch 07.04.2016 Coronary Stents: Past, Present and Future Christoph Kaiser Universitätsspital Basel Rubin GS, The first balloon-expandable coronary stent, University of Queensland Press
Moins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
New Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
Left Main PCI vs. CABG: Real World
Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
ISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli, MD Klinikum der Universitaet Munich Deutsches
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
Interventional Cardiology
Interventional Cardiology Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis
International Scholarly Research Network ISRN Cardiology Volume 2011, Article ID 675638, 6 pages doi:10.5402/2011/675638 Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting
Supplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
DRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
Bifurcations Bad Krozingen I
Bifurcations Bad Krozingen I Clinical outcome 5 years after routine T-Stenting versus provisional T-stenting in the treatment of de novo coronary bifurcation lesions using sirolimus-eluting stents M. Ferenc
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
Clinical Application of OCT in Stent Evaluation
Imaging & Physiology Summit 2010 in Soul #1. Basics of Image Interpretation: IVUS/VH/OCT Clinical Application of OCT in Stent Evaluation Mitsuyasu Terashima, MD, PhD, FACC Stent implantation Stent Apposition
LM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
Supplementary Information for Duration of dual antiplatelet therapy after drug-eluting stent
Supplementary Information for Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials Title of manuscript: Duration of dual antiplatelet
Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023
stent (stent fracture) clopidogrel in stent restenosis drug eluting stent(des) (overlap) mail:
stent (MD) (MD) clopidogrel (stent fracture) in stent restenosis drug eluting stent() stent post dilation, angulated) (overlap) mail: mehrdadsaravi@gmail.com J Babol Univ Med Sci; 11(5); Dec-Jan 2009-2010
EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) Disclosures Investigator Initiated Trial: NCT00828087. Unrestricted grant from Abbott to the Spanish Heart Foundation.
Rationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
Christian Spaulding. for the TYPHOON Investigators
Four-Year Follow-Up of the TYPHOON Study, a Multicenter, Randomized, Single-blind Trial To Assess The Use of the CYPHER Sirolimus-eluting Stent (SES) in Acute Myocardial Infarction Patients Treated With
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
Pravesh Kumar Bundhun 1, Chandra Mouli Yanamala 2 and Wei-Qiang Huang 1*
Bundhun et al. BMC Cardiovascular Disorders (2017) 17:84 DOI 10.1186/s12872-017-0515-4 RESEARCH ARTICLE Open Access Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus
Update on Antiplatelet Therapy
Update on Antiplatelet Therapy Christine Ibarra Pharm.D. PGY-1 Baptist Hospital of Miami Objectives Explain the role of antiplatelettherapy in prevention of cardiovascular events Appreciate differences
The SORT OUT VI Trial
A Prospective, Randomized, "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting Stents The SORT OUT VI Trial Bent Raungaard, Lisette
Nuo Li, Ye-Gui Yang and Meng-Hua Chen *
Li et al. BMC Cardiovascular Disorders (2016) 16:238 DOI 10.1186/s12872-016-0422-0 RESEARCH ARTICLE Open Access Comparing the adverse clinical outcomes in patients with non-insulin treated type 2 diabetes
Drug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
eluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
Safety of Drug-Eluting Stents in Acute Coronary Syndromes
Rotterdam, June 11 th 2012 Safety of Drug-Eluting Stents in Acute Coronary Syndromes Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
PCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
Long-term Outcomes of Paclitaxel-Eluting Versus Sirolimus-Eluting Stent for Percutaneous Coronary Intervention: A Meta-Analysis
META ANALYSIS Long-term Outcomes of Paclitaxel-Eluting Versus Sirolimus-Eluting Stent for Percutaneous Coronary Intervention: A Meta-Analysis Jie Kong, Peng Liu, Xueqiang Fan, Jianyan Wen, Jianbin Zhang,
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
Medical therapy after angioplasty / stenting
Nurse and Technician Forum Part I Medical therapy after angioplasty / stenting Erich Minar Department Angiology Medical University Vienna Disclosure Speaker name: Erich Minar I do not have any potential
The MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
PTCA 1979: : I
The SYNTAX Message is Clear: CABG is Preferred in Complex MVD Angioplasty Summit TCTAP 2012 Seoul, Korea April 2012 David R. Holmes, MD Mayo Clinic Rochester, MN Presenter Disclosure Information David
Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
PCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
Journal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
RESEARCH. Daniele Giacoppo, 1 Giuseppe Gargiulo, 1 Patrizia Aruta, 1 Piera Capranzano, 1,2 Corrado Tamburino, 1,2 Davide Capodanno 1,2.
open access Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 488 patients Daniele Giacoppo, 1 Giuseppe
STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION
STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION Otávio Berwanger, MD, FACS - On behalf of the SECURE Steering Committee and Investigators Trial Organization Trial Steering Committee Dr.
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in costeffectiveness
Burgers et al. BMC Health Services Research (2016) 16:23 DOI 10.1186/s12913-015-1230-4 RESEARCH ARTICLE Using meta-regression analyses in addition to conventional systematic review methods to examine the
Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A
Summary HTA HTA-Report Summary Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Scientific background The coronary heart
Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
SeQuent Please World Wide Registry
Journal of the American College of Cardiology Vol. 6, No. 18, 212 212 by the American College of Cardiology Foundation ISSN 735-197/$36. Published by Elsevier Inc. http://dx.doi.org/1.116/j.jacc.212.7.4
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
Supplementary Online Content
Supplementary Online Content Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals.
Current Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
A BS TR AC T. n engl j med 356;10 march 8,
The new england journal of medicine established in 1812 march 8, 27 vol. 356 no. 1 A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents Christian Spaulding, M.D., Joost Daemen,
Is the role of bivalirudin established?
Is the role of bivalirudin established? Rob Henderson Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals Conflicts of Interest: None Declarations: Member NICE Unstable Angina
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
Bernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent Bernard Chevalier
Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2
Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2 Raban V. Jeger,Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, GregorLeibundgut, Daniel Weilenmann, JochenWöhrle,
Lisette Okkels Jensen
A Randomized Trial Comparing a Polymer- Free Coronary Drug-Eluting Stent With an Ultra-Thin Strut Bioresorbable Polymer- Based Drug-Eluting Stent in an All-Comers Patient Population Lisette Okkels Jensen
Kang Gao, Yiguang Sun * , Ming Yang, Ling Han, Liwei Chen, Wenze Hu, Ping Chen and Xiaohong Li
Gao et al. BMC Cardiovascular Disorders (2017) 17:194 DOI 10.1186/s12872-017-0603-5 RESEARCH ARTICLE Open Access Efficacy and safety of polymer-free stent versus polymer-permanent drug-eluting stent in
Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents
Journal of the American College of Cardiology Vol. 50, No. 14, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.06.029
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
Comparison of Bare metal Vs Drug eluting stents for in-stent Restenosis among Diabetics
Original Article Comparison of Bare metal Vs Drug eluting stents for in-stent Restenosis among Diabetics Mynuddin Ahmed Nawaz 1, Ia Avaliani 1, Irakli Davitashvili 1, Georgi Getmansky 1 Khatuna Jalabadze
Αγγειοπλαστική σε διαβητικούς ασθενείς
Αγγειοπλαστική σε διαβητικούς ασθενείς Σταύρος Χατζημιλτιάδης Επίκουρος Καθηγητής Καρδιολογίας Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Νοσοκομείο ΑΧΕΠΑ Risk of Cardiovascular Outcomes in Diabetics Shramm
Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
Non-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
eucalimus - First Experience
A New Sirolimus Eluting Stent with a Biodegradable Polymer Early and Mid Term Experience with the eucalimus Stent in Egypt Dr. Hossam El Din Mohamed Mansour on behalf of the investigators Ahmed Emara,
Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event. The DES LATE Trial
Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event The DES LATE Trial Cheol Whan Lee, MD, Seung-Jung Park, MD, PhD, On Behalf of the DES LATE Investigators
Smooth muscle pharmacology & interventional cardiology
Smooth muscle pharmacology & interventional cardiology By: Pascal Bernatchez!!!!! LAST LECTURE Classic Vascular pharmacology -chronic -systemic Local Vascular pharmacology -acute -targeted High blood pressure